Literature DB >> 17178798

Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers.

Timothy M E Davis1, Michelle England, Anne-Marie Dunlop, Madhu Page-Sharp, Nathalie Cambon, Thomas G Keller, János L Heidecker, Kenneth F Ilett.   

Abstract

The effect of mefloquine on artesunate pharmacokinetics was assessed in 20 volunteers given artesunate for 3 days, followed > or =21 days later by combination therapy for 3 days. The areas under the concentration-time curve from 0 h to infinity for dihydroartemisinin, the active metabolite of artesunate, were similar on day 3 of the two dosing periods (P = 0.12), implying no interaction.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17178798      PMCID： PMC1803145          DOI： 10.1128/AAC.01253-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria.

Authors:  M Ashton; D S Nguyen; V H Nguyen; T Gordi; N H Trinh; X H Dinh; T N Nguyen; D C Le
Journal:  Clin Pharmacol Ther       Date:  1998-04       Impact factor: 6.875

3.  Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegårdh; Rose McGready; Robert Hutagalung; Rae Hae; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Comparative clinical trial of four regimens of dihydroartemisinin-mefloquine in multidrug-resistant falciparum malaria.

Authors:  K Na-Bangchang; P Tippanangkosol; R Ubalee; S Chaovanakawee; S Saenglertsilapachai; J Karbwang
Journal:  Trop Med Int Health       Date:  1999-09       Impact factor: 2.622

5.  Kinetics of a new antimalarial, mefloquine.

Authors:  R E Desjardins; C L Pamplin; J von Bredow; K G Barry; C J Canfield
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

6.  Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers.

Authors:  E F Boudreau; L Fleckenstein; L W Pang; G E Childs; A C Schroeder; B Ratnaratorn; P Phintuyothin
Journal:  Clin Pharmacol Ther       Date:  1990-10       Impact factor: 6.875

7.  Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults.

Authors:  M Ashton; T N Hai; N D Sy; D X Huong; N Van Huong; N T Niêu; L D Công
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

8.  Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria.

Authors:  T M Davis; H L Phuong; K F Ilett; N C Hung; K T Batty; V D Phuong; S M Powell; H V Thien; T Q Binh
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers.

Authors:  Kevin T Batty; Kenneth E Iletr; Shane M Powell; Jaye Martin; Timothy M E Davis
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

10.  Pharmacokinetics of mefloquine alone or in combination with artesunate.

Authors:  J Karbwang; K Na Bangchang; A Thanavibul; D J Back; D Bunnag; T Harinasuta
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408
View more
  6 in total

1.  Single-dose pharmacokinetic interaction between artesunate and amodiaquine: assembling the clues for the purported interaction.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2008-08-08       Impact factor: 2.953

2.  Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study.

Authors:  Kevin T Batty; Sam Salman; Brioni R Moore; John Benjamin; Sook Ting Lee; Madhu Page-Sharp; Nolene Pitus; Kenneth F Ilett; Ivo Mueller; Francis W Hombhanje; Peter Siba; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 3.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.

Authors:  Joerg J Moehrle; Stephan Duparc; Christoph Siethoff; Paul L M van Giersbergen; J Carl Craft; Sarah Arbe-Barnes; Susan A Charman; Maria Gutierrez; Sergio Wittlin; Jonathan L Vennerstrom
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 5.  Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration.

Authors:  Carrie A Morris; Stephan Duparc; Isabelle Borghini-Fuhrer; Donald Jung; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Malar J       Date:  2011-09-13       Impact factor: 2.979

6.  The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation.

Authors:  S M D K Ganga Senarathna; Madhu Page-Sharp; Andrew Crowe
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.